Tatsuya Ioka

Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

Hideki Ueno, Tatsuya Ioka, Masafumi Ikeda et al. · Journal of Clinical Oncology · 2013 · 624 citations

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

Hedy L. Kindler, Tatsuya Ioka, D. J. Richel et al. · The Lancet Oncology · 2011 · 393 citations

Gemcitabine Versus Placebo, Oncology, Pancreatic Cancer +7

Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial

Chigusa Morizane, Takuji Okusaka, Junki Mizusawa et al. · Annals of Oncology · 2019 · 320 citations

S-1 Versus Gemcitabine, Gastrointestinal Oncology, Medicine +7

Randomized phase <scp>III</scp> study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (<scp>KHBO1401</scp>‐ <scp>MITSUBA</scp>)

Tatsuya Ioka, Masashi Kanai, Shogo Kobayashi et al. · Journal of Hepato-Biliary-Pancreatic Sciences · 2022 · 226 citations · Full text

Phase <scp>II</scp> study of <scp>FOLFIRINOX</scp> for chemotherapy‐naïve Japanese patients with metastatic pancreatic cancer

Takuji Okusaka, Masafumi Ikeda, Akira Fukutomi et al. · Cancer Science · 2014 · 171 citations · Full text